Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LABT Lakewood-Amedex Biotherapeutics (Direct Listing)

盘后交易 07-23 16:35:04 EDT

3.06

-0.35

-10.26%

盘后2.85

-0.21-6.86%

16:35 EDT

最高3.55	最低2.77	成交量200.86万
今开3.55	昨收3.41	日振幅22.87%
总市值535.74万	流通市值177.45万	总股本175.08万
成交额651.13万	换手率346.38%	流通股本57.99万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LABT","market":"US","secType":"STK","nameCN":"Lakewood-Amedex Biotherapeutics (Direct Listing)","latestPrice":3.06,"timestamp":1784836800000,"preClose":3.41,"halted":0,"volume":2008645,"hourTrading":{"tag":"盘后","latestPrice":2.85,"preClose":3.06,"latestTime":"16:35 EDT","volume":20809,"amount":60188.9733219,"timestamp":1784838903427,"change":-0.21,"changeRate":-0.068627,"amplitude":0.071895},"delay":0,"changeRate":-0.1026392961876833,"floatShares":579893,"shares":1750800,"eps":-8.933086,"marketStatus":"盘后交易","change":-0.35,"latestTime":"07-23 16:35:04 EDT","open":3.55,"high":3.55,"low":2.77,"amount":6511305.182987001,"amplitude":0.228739,"askPrice":3.06,"askSize":30,"bidPrice":2.8,"bidSize":150,"shortable":0,"etf":0,"ttmEps":-8.933086,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784851200000},"marketStatusCode":4,"adr":0,"listingDate":1776916800000,"exchange":"NASDAQ","adjPreClose":3.41,"preHourTrading":{"tag":"盘前","latestPrice":3.538,"preClose":3.41,"latestTime":"09:29 EDT","volume":280507,"amount":938920.6882411,"timestamp":1784813396827,"change":0.128,"changeRate":0.037537,"amplitude":0.258065},"postHourTrading":{"tag":"盘后","latestPrice":2.85,"preClose":3.06,"latestTime":"16:35 EDT","volume":20809,"amount":60188.9733219,"timestamp":1784838903427,"change":-0.21,"changeRate":-0.068627,"amplitude":0.071895},"volumeRatio":0.125638},"requestUrl":"/m/hq/s/LABT/wiki","defaultTab":"wiki","newsList":[{"id":"1105205621","title":"Lakewood-Amedex Biotherapeutics 完成感染性糖尿病足溃疡二期a阶段试验最终筹备","url":"https://stock-news.laohu8.com/highlight/detail?id=1105205621","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105205621?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:04","pubTimestamp":1784117062,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已进入其针对感染性糖尿病足溃疡治疗的二期a阶段临床试验的最终准备阶段。公司正集中资源推进试验流程，标志着其核心疗法开发进入关键节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146064134","title":"Lakewood-Amedex Biotherapeutics - Nu-3在临床前研究中展现良好耐受性，高剂量下系统暴露量低","url":"https://stock-news.laohu8.com/highlight/detail?id=1146064134","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146064134?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:03","pubTimestamp":1784117015,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics（直接上市）宣布，其候选药物Nu-3在近期完成的临床前研究中取得了积极结果。数据显示，即使在较高剂量下，Nu-3也表现出良好的耐受性，且系统暴露水平维持在较低范围。这一发现为该药物的进一步开发提供了重要的安全性依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125245294","title":"Lakewood-Amedex Biotherapeutics公布临床前安全性数据，支持Nu-3凝胶即将开展的2a期试验剂量选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1125245294","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125245294?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:03","pubTimestamp":1784116990,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司宣布了其Nu-3凝胶的临床前安全性数据。这些关键数据为即将启动的2a期临床试验中的临床剂量选择提供了有力支持。研究结果表明，Nu-3凝胶在所测试的剂量范围内展现出良好的安全性特征，这为后续临床研究的顺利推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150730441","title":"Lakewood-Amedex Biotherapeutics 准备推进 Nu-3 针对感染性糖尿病足溃疡的二期临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1150730441","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150730441?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:08","pubTimestamp":1783426135,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 正准备将其候选药物 Nu-3 推进至二期临床开发阶段，该药物旨在治疗感染性糖尿病足溃疡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155453862","title":"Lakewood-Amedex Biotherapeutics 宣布普通股1比10反向拆股 - 美国证券交易委员会文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1155453862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155453862?lang=zh_cn&edition=full","pubTime":"2026-06-17 23:42","pubTimestamp":1781710936,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已向美国证券交易委员会提交文件，宣布对其已发行的普通股进行一比十的反向股票分割。\n此项公司行动旨在调整其股本结构。反向拆股预计将于近期生效，具体细节请参阅公司提交的正式监管文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187732926","title":"Lakewood-Amedex Biotherapeutics：关键制剂、递送与生产步骤完成，为计划中的二期临床试验做准备","url":"https://stock-news.laohu8.com/highlight/detail?id=1187732926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187732926?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:06","pubTimestamp":1779105973,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 宣布，已成功完成关键制剂、药物递送及生产工艺步骤，为其计划开展的二期临床试验做好了充分准备。这些进展标志着公司在推进其候选疗法方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165537088","title":"Lakewood-Amedex Biotherapeutics 宣布其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1165537088","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165537088?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:03","pubTimestamp":1779105797,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 公布了其领先候选药物 Nu-3 在治疗感染性糖尿病足溃疡方面取得积极数据，这标志着该药物研发进程的又一重要进展。这些数据为 Nu-3 的进一步临床开发提供了有力支持，有望为这一难治性感染领域带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184734412","title":"Lakewood-Amedex Biotherapeutics 宣布与Peri达成协议，后者将担任Nu-3二期临床试验的合同研究组织","url":"https://stock-news.laohu8.com/highlight/detail?id=1184734412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184734412?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:03","pubTimestamp":1778587406,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics 已正式宣布与Peri公司达成一项合作协议。根据协议条款，Peri公司将作为合同研究组织，负责其候选药物Nu-3的二期临床试验工作。此举标志着该药物研发进程迈入了新的关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161086272","title":"Lakewood-Amedex Biotherapeutics公布针对感染性糖尿病足溃疡的主要候选药物抗微生物耐药性积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161086272","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161086272?lang=zh_cn&edition=full","pubTime":"2026-05-01 20:04","pubTimestamp":1777637056,"startTime":"0","endTime":"0","summary":"Lakewood-Amedex Biotherapeutics公司近日披露了其针对感染性糖尿病足溃疡的主要候选药物在抗微生物耐药性方面取得的积极研究数据。这项进展标志着该公司在开发新型抗菌疗法领域迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://lakewoodamedex.com","stockEarnings":[{"period":"1week","weight":0.4033},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.9606},{"period":"ytd","weight":-0.9574}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":0.0041},{"period":"3month","weight":0.055},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.1885},{"period":"ytd","weight":0.096}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Lakewood-Amedex Biotherapeutics Inc.最初于2006年7月11日在特拉华州注册成立。该公司是一家私营制药公司，专注于通过开发其双磷酸霉素来应对抗菌素耐药性（AMR）的全球健康危机类抗菌剂。该公司的方法涉及一种新机制，旨在迅速破坏细菌膜的稳定性，这可能会降低耐药性发展的可能性。他们的先导化合物Nu-3目前正处于治疗感染的糖尿病足溃疡的临床试验中，被配制为外用凝胶，可提供快速的抗菌作用和靶向递送。除了糖尿病足溃疡，该公司正在探索在治疗复杂的尿路感染和肺部感染方面的应用。","exchange":"NASDAQ","name":"Lakewood-Amedex Biotherapeutics (Direct Listing)","nameEN":"Lakewood-Amedex Biotherapeutics (Direct Listing)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Lakewood-Amedex Biotherapeutics (Direct Listing),LABT,Lakewood-Amedex Biotherapeutics (Direct Listing)股票,Lakewood-Amedex Biotherapeutics (Direct Listing)股票老虎,Lakewood-Amedex Biotherapeutics (Direct Listing)股票老虎国际,Lakewood-Amedex Biotherapeutics (Direct Listing)行情,Lakewood-Amedex Biotherapeutics (Direct Listing)股票行情,Lakewood-Amedex Biotherapeutics (Direct Listing)股价,Lakewood-Amedex Biotherapeutics (Direct Listing)股市,Lakewood-Amedex Biotherapeutics (Direct Listing)股票价格,Lakewood-Amedex Biotherapeutics (Direct Listing)股票交易,Lakewood-Amedex Biotherapeutics (Direct Listing)股票购买,Lakewood-Amedex Biotherapeutics (Direct Listing)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Lakewood-Amedex Biotherapeutics (Direct Listing)(LABT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}